Journal article

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study

Anushi E Rajapaksa, Lien Anh Ha Do, Darren Suryawijaya Ong, Magdy Sourial, Duncan Veysey, Richard Beare, William Hughes, William Yang, Robert J Bischof, Amarin McDonnell, Peter Eu, Leslie Y Yeo, Paul V Licciardi, Edward K Mulholland

Frontiers in Pharmacology | FRONTIERS MEDIA SA | Published : 2020


Objective: Current prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV season. Here we present proof-of-concept data using nebulized palivizumab delivery as a promising new approach for the prevention or treatment of severe RSV infections, documenting both aerosol characteristics and pulmonary deposition patterns in the lungs of lambs. Design: Prospective animal study. Setting: Biosecurity Control Level 2-designated large animal research facility at the Murdoch Children's Research Institute, Melbourne, Australia. S..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC) Early Career Fellowship

Awarded by NHMRC Career Development Fellowship

Funding Acknowledgements

The authors thank Rebecca Sutton for her technical assistance on lamb management, and Kera Pethybridge and Ellie Wright for her technical assistance on nuclear imaging. This study is supported by a Jack Brockhoff Foundation Early Career Research Grant and a National Health and Medical Research Council (NHMRC) Early Career Fellowship (GNT1123030) awarded to AR, and the Victorian Government's Operational Infrastructure Support Program. PL is supported by an NHMRC Career Development Fellowship (GNT1165084).